Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 8/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445818 | 0.82 | EGLN1 (0.62) | KDRTRPV1 | |
| SCHEMBL8764506 | 0.78 | MEN1 (0.66) | TMPRSS4P2RX1P2RX7P2RX4TAS2R14 | |
| SCHEMBL447630 | 0.76 | KDR (0.53) | KDRP2RX1P2RX7P2RX4TUBB4A | |
| SCHEMBL4969614 | 0.76 | KMT2A (0.54) | P2RX1MEN1KMT2AHTTNFKB1 | |
| SCHEMBL3121274 | 0.76 | XPO1 (0.60) | TMPRSS4KDRP2RX1P2RX7P2RX4 | |
| SCHEMBL6815997 | 0.75 | TLR8 (0.58) | TMPRSS4KDRP2RX1P2RX7P2RX4 | |
| SCHEMBL445408 | 0.75 | NTRK3 (0.57) | — | |
| SCHEMBL3894313 | 0.74 | KDR (0.63) | TMPRSS4KDRTUBB4ATUBBTUBA3C | |
| SCHEMBL129638 | 0.74 | TMPRSS4 (0.90) | TMPRSS4KDRP2RX1P2RX7P2RX4 | |
| SCHEMBL3956492 | 0.74 | EGLN1 (0.50) | KDRMEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | TMPRSS4 3685/4885KDR 13/4885P2RX1 1309/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | TMPRSS4 3471/4885KDR 8/4885P2RX1 1318/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | TMPRSS4 2136/4885KDR 18/4885P2RX1 1358/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | TMPRSS4 3396/4885KDR 13/4885P2RX1 1920/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | TMPRSS4 2136/4885KDR 18/4885P2RX1 1358/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | TMPRSS4 3396/4885KDR 13/4885P2RX1 1920/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | TMPRSS4 3471/4885KDR 8/4885P2RX1 1318/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | TMPRSS4 2895/4885KDR 4/4885P2RX1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.